Impact of nafarelin and leuprolide for endometriosis on quality of life and subjective clinical measures

What Was Tested

The paper reports a study of Leuprolide and Nafarelin in the context of endometriosis, published as a randomized controlled trial.

To examine the impact of treating endometriosis with nafarelin or leuprolide acetate depot on patient quality of life (QOL) and subjective clinical measures.

Who Took Part

According to the abstract, 192 women were involved.

PubMed indexes the participants as adults and middle-aged adults, women only.

A randomized, multicenter study was conducted on 192 women with endometriosis.

Patients received nafarelin or leuprolide for six months and were followed for up to six months after treatment.

How the Study Was Run

In design terms this was a randomized and multicenter study.

The women were allocated by chance, so the Leuprolide group and the comparison group should start out alike.

Running at several centres spread the Leuprolide study over different clinics and patient groups.

A time span of six months appears in the methods.

QOL was defined by seven items, including symptom severity, daily activities, pain medication use and need for bed rest.

What Was Measured

PubMed files the paper under topics including Analgesics, Bed Rest, Endometriosis, Fertility Agents, Female, Hormones, Hot Flashes and Leuprolide.

What This Means in Plain Language

The paper is a randomized and multicenter study of Leuprolide and Nafarelin in 192 women in people with endometriosis over six months.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (The Journal of reproductive medicine), a journal based in United States.

More context: the Leuprolide compound page and the Nafarelin compound page, Endometriosis research.